4 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Westlake BioPartners Fund III, L.P.Filed to raise in 2023, with no closing reported yet. | 2023 | $450M | $0 | 0 |
| Westlake BioPartners Opportunity Fund I, L.P. | July 2020 | $100M | $100M | 25 |
| Westlake BioPartners Fund II, L.P.Filed to raise in 2020, with no closing reported yet. | 2020 | $450M | $0 | 0 |
| Westlake BioPartners Fund I, L.P. | August 2018 | $320M | $320M | 33 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
6 partners are named across this firm’s filings, 4 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Beth Seidenberg | Selective | Biotech & pharma, Digital health, Medical devices | 21 |
Classified sectors of Westlake Biopartners’s own portfolio companies, based on 31 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| New Enterprise Associates | 3 | 3-V Biosciences, Ceterix Orthopaedics, TESARO |
| Versant Side | 3 | Cell Design Labs, Ceterix Orthopaedics, REDBRICK HEALTH |
| Sofinnova Venture Partners | 2 | Star Therapeutics, Vera Therapeutics |
| The Column Group |
| 2 |
| David AllisonNot on the current fund | Slowing | Biotech & pharma, Medical devices | 7 | 1 |
| Mira ChaurushiyaNot on the current fund | Slowing | Biotech & pharma | 2 | 1 |
| Peter Calveley | Quiet | None listed | 0 | 0 |
| Scott Ryles | Quiet | None listed | 0 | 0 |
| Sean Harper | Quiet | Fintech, Biotech & pharma | 4 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Westlake Biopartners’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| 2 |
| Flexus Biosciences, RAPT Therapeutics |
| Vida Ventures | 2 | Auxogyn, Cell Design Labs |
| 7wire Ventures | 1 | Livongo Health |
| Amzl | 1 | Auxogyn |
| August Capital Strategic Partners | 1 | Kin Insurance |
| Caduceus Capital | 1 | Star Therapeutics |
| Camber Creek | 1 | Breathe Technologies |
| GC Venture | 1 | Livongo Health |
| General Catalyst | 1 | Livongo Health |
| Longitude Capital | 1 | Vera Therapeutics |
| Orbimed Asia Partners | 1 | Star Therapeutics |
| Orbimed Genesis | 1 | Star Therapeutics |
A shared board seat: a company where filings name a Westlake Biopartners partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.
